CNTB
Connect Biopharma Holdings LimitedNASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
3.96
P/S
0.00
EV/EBITDA
-2.23
DCF Value
$0.64
FCF Yield
-30.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-97.9%
ROA
-99.0%
ROIC
-135.7%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $-48.0K | $-42.6M | $-0.77 |
| FY 2025 | $0.00 | $-55.5M | $-1.00 |
| Q2 2025 | $48.0K | $-12.9M | $-0.23 |
| Q4 2024 | $1.9M | $-23.2M | $-0.42 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllLatest News
Company Info
Sector
Healthcare
Industry
—
Country
CN
Exchange
NASDAQ
Beta
-0.19
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.